文献速递肿瘤 PET/CT

18F-恩杂鲁胺的合成与评价:一种用于雄激素受体PET显像的新型放射性配体与18F-FDHT的比较

Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone.
PubMed 文献 · J Nucl Med · 2021-01-30

本研究将恩杂鲁胺用18F标记,在LNCaP(AR阳性)和HEK293(AR阴性)细胞及LNCaP荷瘤雄鼠中,与现行标准18F-FDHT比较体外摄取、体内PET显像、生物分布和代谢稳定性。

要点

  • 18F-恩杂鲁胺在AR阳性LNCaP荷瘤鼠中肿瘤摄取约为18F-FDHT的3倍。
  • 两种示踪剂在AR阳性细胞中的摄取可被过量5α-二氢睾酮或恩杂鲁胺显著抑制至约50%。

核心结论

  • 尽管18F-恩杂鲁胺表观摩尔活度较低,但其肿瘤摄取高于18F-FDHT且代谢稳定性更好,可能更适合AR PET显像。
  • 作者指出尚需在其他肿瘤动物模型和患者中进一步评估以确认结果。

研究设计与样本

  • 研究通过硝基前体氟化获得18F-恩杂鲁胺,并在LNCaP(AR阳性)与HEK293(AR阴性)细胞中进行体外摄取及竞争实验。
  • 在肩部荷LNCaP异种移植瘤的雄性裸鼠中,比较18F-恩杂鲁胺与18F-FDHT的体内PET显像、离体生物分布和代谢物研究。

主要发现

  • 18F-恩杂鲁胺放射化学产率为1.4% ± 0.9%,表观摩尔活度为6.2 ± 10.3 GBq/µmol;18F-FDHT产率为1.5% ± 0.8%,摩尔活度大于25 GBq/µmol。
  • 与过量5α-二氢睾酮或恩杂鲁胺共孵育可将AR阳性LNCaP细胞对两种示踪剂的摄取显著降低至约50%,AR阴性HEK293细胞无此变化。
  • 荷LNCaP异种移植瘤雄性小鼠的PET与生物分布显示,18F-恩杂鲁胺的肿瘤摄取约为18F-FDHT的3倍。

临床怎么用

  • 18F-恩杂鲁胺有望作为AR PET显像的候选示踪剂,其较高肿瘤摄取和较好代谢稳定性可能利于前列腺癌AR密度评估。
  • 因原文仅基于细胞与LNCaP荷瘤鼠数据,临床转化前仍需其他肿瘤动物模型和患者研究验证。

局限性

  • 研究仅在LNCaP细胞和LNCaP荷瘤雄鼠中进行,未涉及其他肿瘤动物模型或患者。
  • 18F-恩杂鲁胺的表观摩尔活度较低(6.2 ± 10.3 GBq/µmol),且放射化学产率仅1.4% ± 0.9%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

16β-18F-fluoro-5α-dihydrotestosterone (18F-FDHT) is a radiopharmaceutical that has been investigated as a diagnostic agent for the assessment of androgen receptor (AR) density in prostate cancer using PET. However, 18F-FDHT is rapidly metabolized in humans and excreted via the kidneys into the urine, potentially compromising the detection of tumor lesions close to the prostate. Enzalutamide is an AR signaling inhibitor currently used in different stages of prostate cancer. Enzalutamide and its primary metabolite N-desmethylenzalutamide have an AR affinity comparable to that of FDHT but are excreted mainly via the hepatic route. Radiolabeled enzalutamide could thus be a suitable candidate PET tracer for AR imaging. Here, we describe the radiolabeling of enzalutamide with 18F. Moreover, the in vitro and in vivo behavior of 18F-enzalutamide was evaluated and compared with the current standard, 18F-FDHT. Methods:18F-enzalutamide was obtained by fluorination of the nitro precursor. In vitro cellular uptake studies with 18F-enzalutamide and 18F-FDHT were performed in LNCaP (AR-positive) and HEK293 (AR-negative) cells. Competition assays with both tracers were conducted on the LNCaP (AR-positive) cell line. In vivo PET imaging, ex vivo biodistribution, and metabolite studies with 18F-enzalutamide and 18F-FDHT were conducted on athymic nude male mice bearing an LNCaP xenograft in the shoulder. Results:18F-enzalutamide was obtained in 1.4% ± 0.9% radiochemical yield with an apparent molar activity of 6.2 ± 10.3 GBq/µmol. 18F-FDHT was obtained in 1.5% ± 0.8% yield with a molar activity of more than 25 GBq/µmol. Coincubation with an excess of 5α-dihydrotestosterone or enzalutamide significantly reduced the cellular uptake of 18F-enzalutamide and 18F-FDHT to about 50% in AR-positive LNCaP cells but not in AR-negative HEK293 cells. PET and biodistribution studies on male mice bearing a LnCaP xenograft showed about 3 times higher tumor uptake for 18F-enzalutamide than for 18F-FDHT. Sixty minutes after tracer injection, 93% of 18F-enzalutamide in plasma was still intact, compared with only 3% of 18F-FDHT. Conclusion: Despite its lower apparent molar activity, 18F-enzalutamide shows higher tumor uptake and better metabolic stability than 18F-FDHT and thus seems to have more favorable properties for imaging of AR with PET. However, further evaluation in other oncologic animal models and patients is warranted to confirm these results.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Antunes IF, Dost RJ, Hoving HD, et al. Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone. J Nucl Med. 2021. PMID: 33517325. doi:10.2967/jnumed.120.253641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。